Some patients consider traveling abroad for stem cell treatments, often due to broader claims made by international clinics. However, it’s important to understand that regulatory standards vary significantly between countries.
In the United States, tissue products are regulated under a defined FDA framework with requirements for:

• Donor screening and testing
• Processing and handling standards
• Sterility and traceability

In some international settings, these standards may differ, and patients may have less visibility into sourcing, quality control, and safety protocols. There have also been reported cases of serious complications, including infections, following procedures performed in less regulated environments, underscoring the importance of careful evaluation when considering treatment abroad.

At Meeting Point Health, our focus is to provide care within a regulated medical environment, where patient safety and oversight are prioritized. Using regulated U.S tissue products, patients can receive a similarly comprehensive treatment approach that can be administered incrementally and monitored over time.